Transferrin receptor 1 (TFR1/TFRC/CD71)
Transferrin receptor 1 (TFR1), also known as cluster of differentiation 71 (CD71), is a type II transmembrane glycoprotein and a member of the transferrin receptor family. TFR1 is a 97 kDa type II transmembrane glycoprotein expressed as a homodimer, with each monomer linked by disulfide bonds formed between Cys89 and Cys98. Its structure comprises three main regions: a short cytoplasmic N-terminal domain (residues 1–67), a single transmembrane region (residues 68–88), and a large extracellular domain (residues 89–760). The extracellular portion contains the transferrin-binding site, three N-linked glycosylation sites (Asn251, Asn317, and Asn727), and one O-linked glycosylation site (Thr104); these glycosylation modifications are critical for TFR1 function. Crystallographic studies reveal that the extracellular domain of TFR1 adopts a butterfly-like shape, composed of a protease-like domain, an apical domain, and a helical domain, forming a lateral cleft that binds transferrin.
The TFR1 protein exhibits approximately 77% full-length amino acid sequence homology between human (UniProt P02786) and mouse (UniProt Q62351) orthologs. The helical and protease-like domains, which mediate transferrin binding and internalization, are highly conserved (>85–90%), whereas the surface-exposed apical domain shows only about 74% homology, with exposed loops below 60%. This results in a lack of cross-reactivity with mouse orthologs for most human-specific antibodies. Such species differences significantly constrain preclinical safety and efficacy assessments, driving the development of antibodies using cross-species reactive VHH nanobodies or humanized apical domain transgenic mouse models to enable reliable translation for BBB drug delivery and tumor-targeted ADCs.
Transferrin receptor 1 (TFR1) is a core membrane protein regulating cellular iron metabolism, primarily mediating cellular iron uptake by binding to iron-saturated transferrin (holo-Tf). TFR1 exists as a disulfide-linked homodimer, with each monomer comprising an extracellular C-terminal binding domain, a single transmembrane region, and an intracellular N-terminal signaling region. Its extracellular domain binds holo-Tf with high affinity (Kd approximately 10⁻⁹ mol/L), forming a Tf-Fe³⁺-TFR1 complex that enters the cell via clathrin-mediated endocytosis. In the acidic environment of endosomes, Fe³⁺ is released and reduced to Fe²⁺, which is then transported to the cytosol via DMT1 or ZIP14 to participate in heme and iron-sulfur cluster synthesis; the remaining iron is stored in ferritin or the labile iron pool. The apo-Tf-TFR1 complex is recycled to the cell surface and released into the bloodstream at neutral pH, completing the iron uptake cycle. Additionally, TFR1 can mediate the endocytosis of H-ferritin; however, this process requires higher receptor expression levels and differs from the Tf-Fe³⁺ mechanism, as H-ferritin dissociates in endosomes and is subsequently transported to lysosomes for degradation.
TFR1 can also bind to the hereditary hemochromatosis protein HFE, reducing its affinity for transferrin (Tf) and participating in the regulation of hepcidin expression in hepatocytes. Its expression is regulated by intracellular iron levels: it is upregulated during iron deficiency and downregulated during iron overload. It is also modulated by various transcription factors, including HIF-1, c-MYC, GATA1, and estrogen, and undergoes post-transcriptional regulation via iron regulatory proteins (IRP1/2) interacting with iron-responsive elements (IREs) in the mRNA. TFR1 expression is significantly elevated in cells with high iron demand, including erythroid progenitors, activated lymphocytes, tumor cells, and brain capillary endothelial cells. Its iron uptake function not only supports cellular metabolism and proliferation but also maintains iron homeostasis in oligodendrocytes within the nervous system and regulates osteoclast function and sex-related bone remodeling processes in bone metabolism. The high expression of TFR1 in blood-brain barrier (BBB) endothelial cells makes it an important pathway for brain drug delivery. Currently, various bispecific antibodies have been designed to deliver therapeutic antibodies or nucleic acid drugs to intracranial targets, such as Aβ protein, via TFR1-mediated endocytosis. Additionally, antibody-drug conjugates (ADCs) or fusion proteins targeting tumor cells exert anti-tumor effects through iron deprivation or receptor degradation. TFR1 possesses dual attributes as both a "functional delivery target" and a "direct therapeutic target." Future antibody designs can further explore subtype-selective binding, optimization of endocytic kinetics, and tissue-specific expression differences to enhance therapeutic selectivity and reduce systemic toxicity.
The blood-brain barrier (BBB) is a highly selective semipermeable barrier composed of brain capillary endothelial cells, astrocyte end-feet, pericytes, and the basement membrane. Its primary functions include preventing pathogens and toxins from entering the central nervous system (CNS), selectively transporting nutrients, maintaining the homeostatic environment within the brain, and providing immune isolation to prevent inflammatory damage. However, the BBB also severely restricts drug entry into the brain, allowing only lipophilic small molecules with a molecular weight below 400–600 Da to passively diffuse into the CNS. Consequently, more than 98% of small-molecule drugs and virtually all macromolecular drugs (such as antibodies, peptides, proteins, and nucleic acids) cannot effectively cross.
To address this challenge, BBB-crossing delivery technologies are categorized into invasive and non-invasive approaches, with non-invasive strategies being particularly important. These primarily rely on endogenous endocytic mechanisms, including adsorptive-mediated transcytosis (AMT), carrier-mediated transcytosis (CMT), and receptor-mediated transcytosis (RMT). Due to its specificity and efficiency, RMT has become a research hotspot. The key to achieving efficient RMT delivery lies in selecting target receptors that are highly expressed on brain endothelial cells but lowly expressed in peripheral tissues, thereby minimizing peripheral side effects. Although no ideal receptor currently exists, research has focused on a set of candidate targets, including TFR1, melanotransferrin (MTF/CD228), insulin-like growth factor receptor (IGF1R), members of the low-density lipoprotein receptor family (such as LRP1 and LRP2), and the CD98 heavy chain (CD98hc).
TFR1 is highly expressed in brain capillary endothelial cells and is one of the key receptors for BBB penetration. By constructing bispecific antibodies or fusion proteins, with one end binding to TFR1 to achieve BBB penetration and the other end targeting brain targets (such as Aβ, Tau, BACE1, etc.), effective delivery of drugs into the brain parenchyma can be realized.
For example, Trontinemab developed by Roche delivers anti-Aβ antibodies to the brain via TFR1-mediated transport, demonstrating superior brain distribution and plaque clearance capabilities compared to conventional antibodies in Alzheimer's disease models. Denali Therapeutics has also developed a TFR1-based antibody transport platform (ATV/ETV), enabling efficient brain delivery of enzymes and antibodies. The BBB-penetrating capability of TFR1 is not only applicable to neurodegenerative diseases but also offers new therapeutic pathways for brain tumors, acute stroke, and central nervous system infections. Future drug design can further optimize TFR1 binding affinity, endocytic kinetics, and brain-specific expression to enhance delivery efficiency and reduce off-target risks in peripheral tissues.
TFR1 is a core membrane protein for cellular iron uptake, widely expressed in various tissues. Its expression levels are regulated by iron metabolic status, cell proliferation demands, and pathological stimuli. In tumors and central nervous system diseases, TFR1 expression is significantly upregulated, making it an important target for antibody drug delivery and therapeutic intervention. Its expression is restricted and highly regulated in normal tissues, while it is highly expressed in tumors and specific barrier tissues, exhibiting excellent extracellular accessibility and endocytic capacity, making it an ideal target for antibody drug delivery and direct therapy.
① Cell Membrane Localization: TFR1 is a type II transmembrane glycoprotein, primarily localized on the cell surface, mediating the binding and endocytosis of iron-saturated transferrin (holo-Tf). Its extracellular C-terminal domain serves as the antibody binding site, a critical region for antibody drug design, possessing excellent accessibility and endocytic capacity.
② Expression in Normal Tissues:
a. Low Expression Background: In most differentiated mature normal cells, TFR1 expression levels are low.
b. Highly Proliferative Cells: Expression increases in actively proliferating cells, such as basal epidermal cells, intestinal epithelial cells, activated T cells, and B cells.
c. Cells with High Iron Demand: Expression is significant in placental trophoblasts and erythroid progenitor cells (reticulocytes) to meet the iron uptake required for heme synthesis and rapid differentiation.
③ Key Tissue Expression and Delivery Implications:
a. Blood-Brain Barrier (BBB): TFR1 is highly expressed in brain capillary endothelial cells and represents the most prominent pathway for brain antibody delivery. Its receptor-mediated transcytosis (RMT) mechanism is widely utilized for treating brain diseases, such as Alzheimer's disease and glioma.
b. Impact on Delivery Strategies: Since TFR1 is also expressed in peripheral tissues, antibody design must optimize affinity to avoid the "sink effect," where antibodies are extensively bound in peripheral tissues, thereby reducing brain delivery efficiency. Low-affinity antibodies or bispecific antibodies (e.g., Trontinemab, Denali ATV platform) can achieve selective BBB crossing while minimizing peripheral off-target risks.
TFR1 is highly expressed in various malignant tumors, especially in rapidly proliferating cells, where increased iron demand drives the upregulation of TFR1 expression to meet metabolic requirements. Aberrant iron metabolism has been recognized as one of the tumor-specific markers. TFR1 not only mediates iron uptake but also promotes tumor cell proliferation and invasion by regulating the cell cycle, DNA synthesis, and redox reactions. Furthermore, TFR1 plays an important role in the tumor immune microenvironment; its expression is associated with inflammatory factors (such as IL-17 and NF-κB) and immune regulatory pathways (such as JAK-STAT and FOXM1), suggesting its potential involvement in immune escape mechanisms. Therefore, TFR1 serves as both a metabolic target and an immune regulatory node in tumors. Currently, multiple antibody-based drugs have targeted TFR1 through two main strategies: first, leveraging its endocytic capacity to deliver anticancer agents (such as ADCs, PDCs, RNA carriers, etc.); second, using antibodies to block TFR1 function or activate Fc-mediated effector mechanisms (ADCC, ADCP, CDC) to achieve anti-tumor effects. These strategies have entered clinical validation stages in various solid and hematologic tumors.
1. Tumor Diseases
① Solid Tumors: TFR1 is significantly overexpressed in various solid tumors, including breast cancer, lung cancer, liver cancer, pancreatic cancer, esophageal cancer, ovarian cancer, bladder cancer, osteosarcoma, cholangiocarcinoma, renal cancer, and nervous system tumors.
② Hematologic Malignancies: Expression is elevated in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), etc., and is closely associated with disease progression and prognosis.
2. Pathological Regulatory Mechanisms
① Hypoxia and Inflammation: Hypoxia-inducible factor HIF-1 can upregulate TFR1 expression by binding to hypoxia-responsive elements (HRE) in the TFRC promoter region.
② Oncogene Regulation: c-MYC, SRC, SIRT3 deficiency, and estrogen can enhance TFR1 expression through direct or indirect mechanisms, promoting tumor cell proliferation and anti-apoptosis.
③ Iron Addiction Phenomenon: Tumor cells exhibit enhanced dependence on iron uptake, with TFR1-mediated iron uptake becoming a key mechanism for maintaining their high proliferative state.
3. Clinical Significance
① Core Factor in Iron Metabolism Regulation: TFR1 is the primary pathway for cellular iron uptake; its expression level directly affects cell proliferation, differentiation, and energy metabolism, serving as a key regulatory node in tumors, anemia, and nervous system diseases.
② Tumor Marker and Prognostic Indicator: TFR1 has been proposed as a "pan-cancer marker," with its high expression associated with advanced stages and poor prognosis in various tumors.
③ Brain Delivery Pathway: High expression of TFR1 in BBB endothelial cells makes it a preferred target for brain antibody drug delivery. Multiple preclinical studies have validated its delivery efficiency and brain distribution in bispecific antibodies, fusion proteins, and nanocarriers.
④ Off-target Risk and Affinity Optimization: Due to the widespread expression of TFR1 in peripheral tissues, antibody design must balance affinity and endocytic efficiency to avoid peripheral "sink effect" impacting brain delivery. Affinity modulation and antibody configuration optimization are key strategies to improve the therapeutic window.
⑤ Therapeutic and Delivery Target Value: TFR1 can serve both as an antibody drug delivery pathway and as a direct therapeutic target (e.g., ADCs, Fc-effector antibodies), demonstrating broad application prospects in tumors and nervous system diseases.
Trontinemab is a 2+1 bispecific antibody fusion protein developed based on the Roche Brainshuttle™ platform, consisting of the anti-Aβ binding region of gantenerumab and a humanized TfR1 binding module. Its design principle is to maintain high-affinity bivalent binding to Aβ aggregates while enabling blood-brain barrier transcytosis through monovalent TfR1 binding. This structure avoids aberrant Fcγ receptor clustering, thereby reducing the risk of systemic toxicity. SPR assays demonstrated that its affinity for human TfR1 (Kp = 1.31×10⁻⁷ M) is comparable to that for cynomolgus monkey TfR1 (Kp = 2.49×10⁻⁷ M), ensuring cross-species translatability. Compared with gantenerumab, trontinemab significantly enhances brain tissue exposure while preserving Fc function and Aβ binding capacity.
In in vitro experiments, trontinemab exhibited a binding pattern and affinity for fibrillar Aβ40 and Aβ plaques in human AD brain sections similar to those of gantenerumab, confirming the preservation of its antigen-binding region. Its TfR1-binding module maintained monovalent binding when interacting with the TfR1-transferrin complex, without interfering with endogenous ligand binding. Functional assays demonstrated that trontinemab and gantenerumab were comparable in their ability to induce monocytes to secrete cytokines (IP-10), indicating that Fc-mediated effector functions remained intact. Previously, similar structures had been shown to achieve significant plaque clearance at low doses in mouse AD models, providing support for mechanism validation.
In the cynomolgus monkey (Macaca fascicularis) model, a single intravenous dose of trontinemab (10 mg/kg) or gantenerumab (20 mg/kg) was well tolerated. Pharmacokinetic analysis demonstrated that trontinemab achieved brain tissue exposure levels 7–33 times higher than those of gantenerumab, with the most pronounced differences observed in deep brain regions such as the striatum. Immunohistochemistry confirmed that trontinemab distributed into both cerebral vasculature and parenchyma within 24 hours post-dosing and co-localized with microglia, whereas gantenerumab was confined to the vasculature. Based on cross-species PK/PD modeling, a plaque clearance effect equivalent to gantenerumab 600 mg Q4W can be achieved with trontinemab 210 mg Q4W, suggesting that trontinemab may achieve comparable efficacy in the clinic at lower doses.
Latest Clinical Data (Phase Ib/IIa, AAIC 2025, 25-07-28): The latest results from Part 2 (dose expansion) of the Brainshuttle AD study evaluating trontinemab in patients with Alzheimer's disease show that trontinemab continues to demonstrate rapid and significant amyloid plaque clearance. In the highest dose group, 91% of subjects converted to amyloid-negative status on amyloid positron emission tomography (PET) assessment. The incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) remained below 5%, and infusion-related reactions (IRR) were effectively managed through premedication protocols. Roche plans to launch two pivotal Phase 3 clinical trials later in 2025.
In addition, Roche is expanding the application of its Brainshuttle™ platform to therapeutic research for multiple sclerosis (MS). MS is a chronic autoimmune disease characterized by the immune system attacking the myelin sheath of nerve fibers, leading to neurological impairment, with B cells playing a critical role in disease pathogenesis. R6035, an investigational drug developed by Roche, combines an anti-CD20 antibody with a Brainshuttle™ module. It leverages TfR1-mediated transcytosis to achieve efficient delivery of antibodies into the central nervous system, thereby targeting and clearing B cells within the brain. Compared to traditional anti-CD20 antibody therapies (such as Ocrevus), R6035 is expected to enhance brain tissue targeting and efficacy while reducing peripheral side effects. Currently, R6035 is in Phase 1 clinical trials, primarily assessing its safety and pharmacokinetics. The potential indications for this drug include patients with primary progressive, relapsing-remitting, and secondary progressive MS.
As a delivery platform, the market demand for TFR1 is closely linked to the market demand for the "cargo" it carries—therapeutic drugs. Currently, there is a significant unmet medical need globally in the fields of central nervous system (CNS) diseases, rare diseases, and oncology, providing vast market potential for the TFR1 delivery platform.
① Alzheimer's Disease (AD): Approximately 50 million people worldwide are affected by AD, which is the leading cause of dementia in the elderly. Existing large-molecule anti-Aβ or anti-Tau antibodies have limited therapeutic efficacy due to their inability to effectively cross the blood-brain barrier (BBB), often requiring high-dose administration. The TFR1 delivery platform offers an innovative solution for AD treatment by enhancing brain drug exposure and target clearance efficiency, as demonstrated by the significant advantages of Trontinemab in clinical trials.
② Parkinson's Disease (PD): Over 10 million people worldwide suffer from PD, characterized by the aggregation of α-synuclein protein in the brain. Antibodies targeting α-synuclein similarly face BBB limitations. The TFR1 delivery technology can effectively transport antibodies to the brain, potentially improving both motor and non-motor symptoms.
③ Lysosomal Storage Disorders (LSDs): These rare genetic diseases often present with CNS symptoms, but traditional enzyme replacement therapies (ERT) cannot penetrate the BBB. The TFR1 platform can efficiently deliver enzyme-based drugs, such as Denali's DNL310, offering potential curative solutions for conditions like MPS II.
④ Muscle Diseases: Rare diseases such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) urgently require drugs capable of efficiently delivering oligonucleotides (e.g., ASO, PMO) to muscle tissue. Due to the high expression of TFR1 on muscle cells, it serves as an ideal delivery target for nucleic acid drugs. Companies such as Avidity and Dyne have already advanced into clinical development using this platform.
⑤ Brain Tumors: Malignant tumors such as gliomas respond poorly to existing therapies, partly because chemotherapy drugs and antibodies cannot effectively cross the BBB. The TFR1 delivery platform can directly deliver antibody-drug conjugates (ADCs) or gene therapy vectors to intracranial tumor lesions, potentially improving therapeutic efficacy while reducing systemic toxicity.
⑥ CNS Infections: For conditions such as viral encephalitis, the TFR1 platform can be used to deliver antibodies or antiviral drugs, rapidly penetrating the BBB to control infections.
In summary, as a drug delivery platform, TFR1 addresses the critical challenge of drugs failing to reach their targets in diseases with high incidence, high mortality, and significant limitations in existing therapies, thereby meeting substantial unmet medical needs. With the continuous development of TFR1-based bispecific antibodies, nucleic acid conjugates, and gene therapy vectors, the TFR1 delivery platform is progressively fulfilling clinical needs across different regions globally and driving sustained market growth.
The competitive landscape in the TFR1 delivery platform sector is highly concentrated, with established giants entering the field alongside the continuous emergence of emerging innovative technological pathways.
① Leading Companies: Roche, Denali, Avidity, and others have captured significant platform market share, with core products advancing to late-stage clinical trials or receiving approval. Roche's Brainshuttle™ (Trontinemab) and Denali's ATV/ETV platform are currently the most mature and representative technologies.
② Diversified Technological Pathways: The core competition in TFR1 delivery platforms lies in the design of the "shuttle." The focus of competition has shifted from "whether delivery is possible" to "how to deliver better," reflected in the following aspects.
a. Affinity Modulation: To balance brain delivery efficiency with peripheral "sink effects," various platforms adopt different affinity strategies. Both Roche's Brainshuttle™ and Denali's ATV/ETV platform utilize low or moderate affinity (nM level) to avoid receptor saturation and degradation.
b. Molecular Configuration: From Roche's "2+1" bispecific antibody configuration (Fab) to Denali's Fc region engineering platform, and further to BioArctic's scFv and Aliada's VHH, various molecular formats are exploring optimal delivery efficiency and safety.
c. "Cargo" Diversity: Competition is also reflected in the types of "cargo" that can be carried. Avidity and Dyne focus on nucleic acid drugs (ASO/siRNA), JCR focuses on gene therapy vectors (AAV), while Roche and Denali primarily concentrate on antibody and enzyme-based therapeutics.
③ Strategic Partnerships and Acquisitions: The immense potential of TFR1 delivery platforms has attracted active deployment by major pharmaceutical companies. For instance, AbbVie acquired Aliada Therapeutics, while Bristol Myers Squibb reached a high-value collaboration agreement with Avidity. These moves indicate that platform companies mastering core TFR1 delivery technologies are becoming targets for acquisition or collaboration by industry giants, possessing significant commercial potential and investment value.
④ Pipeline Distribution and Trends: Currently, there are over 80 active TFR1-targeting or delivery pipelines, with the majority concentrated in the preclinical stage (75/86), while few are in Phase 1/2 clinical trials (8/86). JCR Pharmaceuticals' IDS fusion protein based on TFR1 antibodies was approved for marketing in 2021 for the treatment of Mucopolysaccharidosis Type II. Other Phase 3 clinical pipelines include Delpacibart Etedesiran (DMPK) and Delpacibart Braxlosiran (DUX4) for myotonic dystrophy and facioscapulohumeral muscular dystrophy, respectively, developed by Avidity Biosciences using its TFR1 AOC platform. The drug types are predominantly antibody-based. Regarding target combinations, most are currently dual-target drugs. In terms of indications, they mainly focus on CNS diseases, tumors (especially brain tumors), and muscular disorders.
Overall, the TFR1 delivery target market is in a stage of rapid development. Despite intense competition, its vast unmet medical needs and diverse technological pathways provide innovators with broad room for differentiation. The key to project success lies in developing next-generation platforms with superior delivery efficiency, higher safety, and broader compatibility with various molecular types, thereby standing out in the fierce market competition.
TFR1 is a core type II transmembrane glycoprotein that regulates cellular iron metabolism. It binds holo-Tf with high affinity as a homodimer and mediates iron endocytosis and transcellular transport via the clathrin-mediated receptor-mediated transcytosis (RMT) mechanism. Its extracellular domain consists of three structural regions: Protease-like, Apical, and Helical, containing three N-glycosylation sites and one O-glycosylation site, providing excellent accessibility and endocytic compatibility for antibody binding and blood-brain barrier (BBB) delivery. TFR1 is significantly upregulated in erythroid progenitor cells, tumor cells, activated immune cells, and brain capillary endothelial cells. It not only supports cell proliferation and metabolic remodeling but also participates in the regulation of the tumor immune microenvironment and HFE-mediated hepcidin expression, possessing dual attributes as both a functional delivery vehicle and a direct therapeutic target.
Currently, various bispecific antibodies and fusion proteins based on the TFR1 delivery mechanism have entered clinical or preclinical validation: Roche's Brainshuttle™ platform drug Trontinemab (TfR1×Aβ bispecific antibody) has shown an 8-fold increase in cerebrospinal fluid/plasma ratio, a 91% PET negativity rate (at 28 weeks), and ARIA-E <5% in Alzheimer's disease patients; Denali's ATV/ETV platform drug Tividenofusp Alfa (DNL310) has received FDA priority review for MPS II; Aliada/Avidity's TFR1-AOC platform (ASO/PMO conjugates) is in clinical development for DMD and DM1; JCR's JUST-AAV and Regeneron's TfR1-conjugated AAV platforms have also demonstrated efficient brain gene drug delivery in non-human primate and humanized mouse models.
TFR1 offers dual delivery advantages in the BBB RMT pathway and in tissues with high expression in tumors and muscles. Coupled with its extensive application and clinical validation experience across various formats such as BsAbs, Traps, AOCs, ADCs, and gene therapy vectors, as well as its potential in high-unmet-need areas including Alzheimer's disease, Parkinson's disease, lysosomal storage disorders, brain tumors, and rare myopathies, TFR1 is poised to become a transformative target for treating numerous common or rare neurological and muscular diseases.